MARVIN I. SIEGEL, PH.D
SENIOR PHARMACEUTICAL/BIOTECH EXECUTIVE
Senior Executive leader with expertise building companies and managing strategic alliances.
Member of board of directors of two biotech companies. Managed a joint venture between two
biotechnology companies and a $200 million joint development program between a biotech and
a major pharmaceutical company. Negotiated and managed a $20M European process development and manufacturing contract and one in the US. Executed development program
for successful out-license of a product candidate. Demonstrated expertise in strategic planning,
competitive intelligence, business development and leadership of business leaders, scientists
and physicians. Successfully managed multi-disciplinary teams and executed large projects in
the US and Globally. Managed R & D for Claritin, Nasonex, Asmanex and Elocon. Author of 170
publications and holder of 22 patents. Ph.D. Physiological Chemistry, The Johns Hopkins School
of Medicine; M.A. Chemistry, Columbia University; B.S. Chemistry, Lafayette College; Advanced
Management Program, Fuqua School of Business, Duke University.
> Organizational Development > Joint Venture/Corporate Alliance
Intellectual Property > R & D
the research that resulted in the marketing of Claritin, the world’s leading non-
sedating antihistamine, producing annual sales of more than $4 billion. Led the R & D
resulting in the marketing of Nasonex, Asmanex and Elocon, each with annual sales of
the entire program of research, process development, manufacturing, clinical and
regulatory affairs for a biotech company’s first IND through Phase III trials.
semi-annual reviews of business strategy objectives to determine changes
necessary to meet overall objectives. Sometimes required revising short term plans.
and led the US Division of Canadian Biotechnology Company, recruiting and
hiring experienced professional staff and leading “virtual office” for process
development, manufacturing, clinical and regulatory affairs as well as project management. Managed $30M peak annual Research and Development Budget.
a need for additional capital when taking over day to day operational
decisions, approached potential investors, identified and secured $15M in mezzanine
and secured a US intermediary to identify and mold a new approach to
finding US investors for a Canadian public company in need of capital. Identified a
colleague in NY and collaboratively secured US investment that gave the needed comfort
to Canadian investors raising $19 million.
Consulting company to Biotech and Pharmaceutical companies
Consultant to entrepreneurs and entrepreneurial companies with projects in Drug
Development, Strategic Planning and Organizational Development
Clients include companies in Biotech, Pharmaceuticals and Consumer Products.
Chairman, Board of Directors, Acting Chief Executive Officer
Guided strategic planning and corporate development
STRESSGEN BIOTECHNOLOGIES VICTORIA, BC CANADA & COLLEGEVILLE, PA
Development of novel therapeutic vaccines.
Executive Vice President
Led Research, Development, Medical and Regulatory Affairs taking biomolecule from
Headed operating committee for a $20M joint venture.
Negotiated contract and managed $20M international process development and
Represented company to investment analysts, venture capitalists and individual
DELTA PHARMACEUTICALS INC. (NOW ARDENT) DURHAM, NC
Discovery and development of novel drugs for management of acute and chronic pain.
Member, Board of Directors
Guided strategic planning, organizational and business development and provided lead
TERRAPIN TECHNOLOGIES (NOW TELIK) PALO ALTO, CA
Drug discovery in oncology, diabetes and allergy.
Identified, negotiated and secured $15M of mezzanine financing
Responsible for R & D programs for the company
SCHERING PLOUGH (NOW MERCK) KENILWORTH, NJ
Global Pharmaceutical Company with revenues exceeding $6B
Vice President (Presidential Fellow)
Led R & D for Claritin, Asmanex, Nasonex and Elocon
Ph.D Physiological Chemistry The Johns Hopkins University School of Medicine
M.A. Chemistry Columbia University
B.S. Chemistry Lafayette College
Advanced Management Program Fuqua School of Business, Duke University
WATERSTOFPEROXIDE. Bergschenhoek, 21 sept. 2011 . In 1978 is bij mij S.L.E.geconstateerd. S.L.E. staat voor systemische lupus erythematodus, dit is een autoimmuunziekte. Na 15 jaar zeer ernstig ziek te zijn geweest kwam er een verbetering. September 1986 kreeg ik ernstige maagklachten.erbij. Dit kwam door de S.L.E.en het vele medicijn gebruik. Prednison, endoxan dit laatste is zeer schadelijk voo
33° Congresso Nazionale della Società Italiana di Farmacologia SAFETY AND EFFICACY OF EXENATIDE OVER 16 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS USING A THIAZOLIDINEDIONE WITH OR WITHOUT METFORMIN Zinman Bernard 1, Hoogwerf Byron 2, Duran Garcia Santiago 3, Milton Denai 4, Giaconia Joseph 4, Kim Dennis 5, Gentilella Raffaella 6, Trautmann Michael 7, Brodows Robert 4 1 Sinai